Previous 10 | Next 10 |
CRANBURY, N.J., April 15, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in a poster at the American Society of Gene ...
AVROBIO (NASDAQ: AVRO ) initiated with Buy rating at Janney Montgomery Scott. More news on: AVROBIO, Inc., Amicus Therapeutics, Inc., Celgene Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
The USPTO has issued two new patents to Amicus Therapeutics (NASDAQ: FOLD ) directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, to enhance uptake. ...
CRANBURY, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-gluco...
Amicus Therapeutics, Inc. (FOLD) Q4 2018 Results Earnings Conference Call February 28, 2019, 08:30 AM ET Company Participants Sara Pellegrino - Vice President of Investor Relations and Corporate Communication John Crowley - Chairman and Chief Executive Officer Bradley Campbell - ...
Amicus Therapeutics ( FOLD +2.5% ) FY results : Revenues: $91.2M (+147.2%). More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary Read more ...
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Amicus Therapeutics (NASDAQ: FOLD ): FY GAAP EPS of -$1.88. More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M FY18 Galafold Revenue of $91.2M Reflects 650+ Fabry Patients Treated at end of 2018 - 1,000+ Patients Expected by end of 2019 Clinical Data Out to Month 24 and Bre...
AAON , ABB , ACIW , AKRX , AMCX , AMRX , BCPC , BID , BMCH , BPMP , BUD , CARS , CM , CMD , CNP , CROX , CWEN , CWT , DAVA , DEA , EGRX , ENDP , EXLS , FOLD , FRO , FSS , GOLF , GTN , GTT , HMHC , HRI , IBP , ICPT , IRDM , JCP , JD , KDP , LAUR , LKQ ,...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....